首页 > 市场调查报告书 > 製药

动物用医药

市场调查报告书

商品编码

1577001

伴侣兽药市场、机会、成长动力、产业趋势分析与预测，2024-2032

Companion Animal Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月02日 | 出版商:

Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球伴侣动物药物市场价值为196 亿美元，2024 年至2032 年间将以7.5% 的复合年增长率增长，原因是可在动物和人类之间传播的人畜共患疾病的患病率不断上升。随着人们对这些疾病的认识不断提高，宠物主人和兽医越来越关注预防保健和治疗，以确保动物和人类的健康。此外，人们对整体动物健康的认识不断增强，以及及时兽医护理的重要性也进一步增加了对伴侣动物药物的需求。对预防和治疗的高度重视将显着扩大市场。

伴侣动物药品产业根据产品、动物类型、给药途径、配销通路和地区而分散。

由于对宠物感染、过敏和慢性病等各种疾病的有效治疗的需求不断增长，药品领域在 2023 年将保持 54.2% 的份额。该细分市场受益于兽药的不断进步以及宠物主人对动物医疗保健重要性的认识不断提高。随着越来越多的宠物主人优先考虑预防和治疗护理，解决广泛健康问题的创新药物的需求将主导市场。

到 2032 年，由于养狗人数众多以及兽医护理需求不断增长，狗类市场将以 7.4% 的复合年增长率增长。狗通常需要定期治疗感染、过敏和关节炎等慢性疾病，这使它们成为兽药公司的主要关注点。随着人们越来越重视预防保健、疫苗接种和先进治疗，对专门针对狗的药物的需求将保持强劲，从而促进市场扩张。

由于其完善的宠物医疗基础设施、较高的宠物拥有率以及人们对动物健康意识的不断增强，到 2032 年，北美地区的市场规模将扩大到 145 亿美元。该地区受益于强大的兽药公司和先进的研究设施，推动了宠物药物的创新。此外，宠物护理支出的增加和宠物保险的广泛普及进一步支持了市场的成长。北美强大的兽医生态系统使其成为伴侣动物药品市场的显着贡献者。

产业格局，2018 - 2032
产业影响力
- 成长动力
  - 全球宠物保险需求激增
  - 伴侣动物肥胖率上升
  - 增加政府对全球宠物照护的支持
  - 对网路兽药局的需求不断增长
- 产业陷阱与挑战
  - 与伴侣动物药物相关的高成本
成长潜力分析
监管环境/政策环境
- 我们
- 欧洲
- 亚太
差距分析
消费者行为趋势
产业生态系统
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
- Zoetis Inc.
- Boehringer Ingelheim International GmbH
- Elanco Animal Health Incorporated
公司市占率分析
公司矩阵分析
战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 - 2032 年

主要趋势
药品
- 抗寄生虫药
- 消炎剂
- 抗感染药
- 皮质类固醇
- 镇静剂
- 心血管药物
- 胃肠道药物
疫苗
- 改良活疫苗 (MLV)
- 灭活灭活疫苗
- 重组疫苗
药用饲料添加剂
- 抗生素
- 维生素
- 胺基酸
- 酵素
- 抗氧化剂
- 益生元和益生菌
- 矿物质
- 碳水化合物
- 丙二醇

第 6 章：市场估计与预测：按动物类型，2018 年 - 2032 年

主要趋势
狗
猫
马匹
其他动物

第 7 章：市场估计与预测：按管理途径，2018 年 - 2032 年

主要趋势
口服
可注射
专题
其他给药途径

第 8 章：市场估计与预测：按配销通路，2018 年 - 2032 年

主要趋势
兽医院药房
零售药房
电子商务

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 波兰
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 台湾
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 海湾合作委员会国家
- 以色列
- 中东和非洲其他地区

第 10 章：公司简介

Agrolabo SpA
Boehringer Ingelheim International GmbH
Ceva Sante Animale
Chanelle Pharma
Dechra Pharmaceuticals PLC
Elanco Animal Health Incorporated
Endovac Animal Health
HIPRA
Indian Immunologicals Ltd.
Merck and Co., Inc.
Norbrook
Symrise
Vetoquinol
Virbac
Zoetis Inc.

简介目录

Product Code: 4981

The Global Companion Animal Drugs Market was valued at USD 19.6 billion in 2023 and will grow at a 7.5% CAGR between 2024 and 2032, attributed to the rising prevalence of zoonotic diseases, which can be transmitted between animals and humans. As awareness of these diseases increases, pet owners and veterinarians are focusing more on preventive care and treatments to safeguard animal and human health. Also, growing awareness of overall animal health and the importance of timely veterinary care is further boosting demand for companion animal drugs. This heightened focus on prevention and treatment will expand the market significantly.

The companion animal drugs industry is fragmented based on product, animal type, route of administration, distribution channel, and region.

The drugs segment upheld a 54.2% share in 2023 due to the growing demand for effective treatments for various conditions, such as infections, allergies, and chronic diseases in pets. This segment benefits from continuous advancements in veterinary pharmaceuticals and increasing awareness among pet owners about the importance of medical care for animals. As more pet owners prioritize preventive and therapeutic care, the need for innovative drugs to address a wide range of health issues will dominate the market.

The dog segment will grow at a 7.4% CAGR through 2032, driven by the high number of dog owners and the increasing demand for veterinary care. Dogs often require regular treatments for infections, allergies, and chronic conditions like arthritis, making them a primary focus of veterinary pharmaceutical companies. With a growing emphasis on preventive care, vaccinations, and advanced treatments, the demand for drugs specifically tailored to dogs will remain strong, contributing to the market expansion.

North America will expand to USD 14.5 billion by 2032, owing to its well-established pet healthcare infrastructure, high pet ownership rates, and growing awareness of animal health. The region benefits from a strong presence of veterinary pharmaceutical companies and advanced research facilities, driving innovation in pet medications. Besides, increasing expenditures on pet care and the widespread availability of pet insurance further support market growth. North America's robust veterinary ecosystem makes it a notable contributor to the companion animal drugs market.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Surging demand for pet insurance policies worldwide
  - 3.2.1.2 Rising rate of obesity in companion animals
  - 3.2.1.3 Increasing government support for pet care across the globe
  - 3.2.1.4 Growing demand for online veterinary pharmacies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost associated with companion animal drugs
3.3 Growth potential analysis
3.4 Regulatory landscape/policy landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.4.3 Asia-Pacific
3.5 Gap analysis
3.6 Consumer behavior trends
3.7 Industry ecosystem
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
- 4.1.1 Zoetis Inc.
- 4.1.2 Boehringer Ingelheim International GmbH
- 4.1.3 Elanco Animal Health Incorporated
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Drugs
- 5.2.1 Antiparasitic
- 5.2.2 Anti-inflammatory
- 5.2.3 Anti-infectives
- 5.2.4 Corticosteroids
- 5.2.5 Tranquilizers
- 5.2.6 Cardiovascular drugs
- 5.2.7 Gastrointestinal drugs
5.3 Vaccines
- 5.3.1 Modified live vaccines (MLV)
- 5.3.2 Killed inactivated vaccines
- 5.3.3 Recombinant vaccines
5.4 Medicated feed additives
- 5.4.1 Antibiotics
- 5.4.2 Vitamins
- 5.4.3 Amino acids
- 5.4.4 Enzymes
- 5.4.5 Antioxidants
- 5.4.6 Prebiotics and probiotics
- 5.4.7 Minerals
- 5.4.8 Carbohydrates
- 5.4.9 Propandiol

Chapter 6 Market Estimates and Forecast, By Animal Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Dogs
6.3 Cats
6.4 Horses
6.5 Other animals

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Topical
7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Veterinary hospital pharmacy
8.3 Retail pharmacy
8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Poland
- 9.3.7 Netherlands
- 9.3.8 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Taiwan
- 9.4.7 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 GCC Countries
- 9.6.3 Israel
- 9.6.4 Rest of Middle East and Africa